These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 32111969

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
    Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, Diaz de la Guardia R, Castaño J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P.
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS, McCue D, Pemmaraju N.
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.
    Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X.
    Hum Gene Ther; 2010 Jan; 21(1):75-86. PubMed ID: 19719389
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen RWJ, Mutis T, Themeli M.
    Clin Cancer Res; 2019 Jul 01; 25(13):4014-4025. PubMed ID: 30979735
    [Abstract] [Full Text] [Related]

  • 29. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L, Liu X, Wang X, Sun Z, Song XT.
    Leuk Res; 2016 Feb 01; 41():76-84. PubMed ID: 26740053
    [Abstract] [Full Text] [Related]

  • 30. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR, Pemmaraju N.
    Expert Opin Pharmacother; 2022 Mar 01; 23(4):431-438. PubMed ID: 35060807
    [Abstract] [Full Text] [Related]

  • 31. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA.
    Leuk Lymphoma; 2024 May 01; 65(5):548-559. PubMed ID: 38391126
    [Abstract] [Full Text] [Related]

  • 32. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
    Tang H, Panse G, Braddock D, Perincheri S, Xu ML, McNiff JM.
    J Cutan Pathol; 2023 Jul 01; 50(7):595-600. PubMed ID: 37082914
    [Abstract] [Full Text] [Related]

  • 33. BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity.
    Poussard M, Philippe L, Fredon M, Bôle-Richard E, Biichle S, Renosi F, Perrin S, Kroemer M, Limat S, Bonnefoy F, Daguindau E, Deconinck E, Gruson B, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F.
    EJHaem; 2021 Feb 01; 2(1):125-130. PubMed ID: 35846081
    [Abstract] [Full Text] [Related]

  • 34. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN, Rietberg SP, Bonifant CL.
    Cytotherapy; 2018 Oct 01; 20(10):1259-1266. PubMed ID: 30309710
    [Abstract] [Full Text] [Related]

  • 35. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV.
    Mol Ther; 2018 Apr 04; 26(4):986-995. PubMed ID: 29503195
    [Abstract] [Full Text] [Related]

  • 36. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 37. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY, Konopleva M, Pemmaraju N.
    Cancer; 2024 Jul 01; 130(13):2260-2271. PubMed ID: 38620053
    [Abstract] [Full Text] [Related]

  • 38. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, Jin T, Xie R, Wei B, Chen J, Fang H, Han X, Rohrs JA, Bryson P, Liu Y, Li QJ, Zhu B, Wang P.
    Mol Ther; 2018 Apr 04; 26(4):976-985. PubMed ID: 29503204
    [Abstract] [Full Text] [Related]

  • 39. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
    Kerr D, Sokol L.
    Expert Opin Investig Drugs; 2018 Sep 04; 27(9):733-739. PubMed ID: 30118336
    [Abstract] [Full Text] [Related]

  • 40. Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset.
    Yu H, Zhang P, Yin X, Yin Z, Shi Q, Cui Y, Liu G, Wang S, Piccaluga PP, Jiang T, Zhang L.
    Protein Cell; 2015 Apr 04; 6(4):297-306. PubMed ID: 25779340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.